The Risk of Malignancy in the
Surgical Margin at Radical
Prostatectomy Reduced Almost
Three-Fold in Patients Given
Neo-Adjuvant Hormone Treatment

Hugosson, Jonas; Pa, Abrahamsson; Ahlgren, Göran; G, Aus; Lundberg, Susanne; Schelin, Sonny; Schain, Moddy; Pedersen, Katja Venborg

doi:10.1159/000473789

Cited by 51 publications

(35 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The positive margin rate was 5.8%, lower than that reported after 3 months of NHT in similar cohorts of patients 34,36,37 (Figure 3). No cancer was identi®ed in the radical prostatectomy specimen in 13% of cases.…”

Section: Clinical Studies With Long-term Neoadjuvant Therapycontrasting

confidence: 52%

Neoadjuvant hormonal therapy prior to radical prostatectomy: promises and pitfalls

Gleave

Bianca

Goldenberg

2000

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

Section: Clinical Studies With Long-term Neoadjuvant Therapycontrasting

confidence: 52%

Neoadjuvant hormonal therapy prior to radical prostatectomy: promises and pitfalls

Gleave

Bianca

Goldenberg

2000

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…For irradiated patients, NHT was administered throughout the course of radiotherapy. NHT was also given to 51% of the patients in the RP group who were participating in a clinical study (11).…”

Section: Neoadjuvant Hormonal Therapy (Nht)mentioning

confidence: 99%

Long-term health-related quality of life after curative treatment for prostate cancer: A regional cross-sectional comparison of two standard treatment modalities

Hjälm-Eriksson

Lennernäs

Ullén

et al. 2014

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Effects on long-term health-related quality of life (HRQoL) were evaluated in patients treated for localized prostate cancer by two standard modalities: radical retropubic prostatectomy (RP) and external beam radiotherapy combined with a high-dose-rate brachytherapy boost (HDRBT-EBRT). The HRQoL data were compared with age-adjusted normative data. Men diagnosed with localized prostate cancer and treated with curative intent in Gothenburg, Sweden, 1988Sweden, -1997 were included. HRQoL was measured in October 2000 using the EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires, with a response rate of 82% (n=347). No differences in patient characteristics were found between the two treatment groups, except regarding tumor stage and PSA recurrence at the time of the questionnaires. In the RP group, 42% had T1 and 6% had T3-4 tumors; corresponding proportions in the HDRBT-EBRT group were 29% and 13% (P=0.01). PSA recurrence was detected in 44% of RP patients and 9% of HDRBT-EBRT patients. In most domains, mean HRQoL scores were high and similar to the scores for the age-adjusted normative sample. However, patients reported better role and physical function compared to the normal population. We also observed more sleeping disturbances but less pain among patients than in the normal population. The disease-specific questionnaires showed statistically significant higher levels of bowel and urinary problems in the irradiated group than in the RP group, and the absolute difference between the groups was small and had minor clinical significance. We conclude that overall the general quality of life was rated high by the patients irrespective of curative treatment modality and in agreement with age-adjusted normative data. Statistically significant differences in bowel and urinary symptoms were found between the two treatment groups in favor of the RP group, but the clinical significance was small.

show abstract

“…Five of the 12 trials presented pathological results obtained immediately postoperatively. 14,[18][19][20][21] Longer term follow-up was not available from these studies. The remaining studies followed patients from 5 months to 5 years post-operatively.…”

mentioning

confidence: 99%

“…All four studies that compared rates of positive surgical margins (unfavourable outcome) between NHT + RP and RP-only groups [18][19][20] found statistically significant differences postoperatively in favour of the NHT patients: 23 versus 41% ( p = 0.013), 13 versus 38.5% ( p = 0.0006), 19 versus 46% ( p = 0.01) and 7.8 versus 33.8% ( p < 0.0001). Gleave and co-workers compared 3 months and 8 months preoperative therapy.…”

mentioning

confidence: 99%

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

Hummel

Paisley²,

Morgan³

et al. 2003

Health Technol Assess

107

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. The editors and publisher have tried to ensure the accuracy of this report but do not accept liability for damages or losses arising from material published in this report. HTAISSN 1366-5278 © Queen's Printer and Controller of HMSO 2003This monograph may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.Applications for commercial reproduction should be addressed to HMSO,The Copyright Unit, St Clements House, 2-16 Colegate, Norwich, NR3 1BQ.Published by Gray Publishing, Tunbridge Wells, Kent, on behalf of NCCHTA.Printed on acid-free paper in the UK by St Edmundsbury Press Ltd, Bury St Edmunds, Suffolk. Criteria for inclusion in the HTA monograph seriesReports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

show abstract

The Risk of Malignancy in the Surgical Margin at Radical Prostatectomy Reduced Almost Three-Fold in Patients Given Neo-Adjuvant Hormone Treatment

Cited by 51 publications

References 10 publications

Neoadjuvant hormonal therapy prior to radical prostatectomy: promises and pitfalls

Neoadjuvant hormonal therapy prior to radical prostatectomy: promises and pitfalls

Long-term health-related quality of life after curative treatment for prostate cancer: A regional cross-sectional comparison of two standard treatment modalities

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

Contact Info

Product

Resources

About